Cerecor Inc. (NASDAQ:CERC) is scheduled to be issuing its quarterly earnings data on Monday, August 14th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.

Cerecor (NASDAQ:CERC) last released its quarterly earnings results on Tuesday, May 9th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.18. Cerecor had a negative net margin of 864.87% and a negative return on equity of 896.66%. The firm had revenue of $0.38 million during the quarter. On average, analysts expect Cerecor to post $-0.97 EPS for the current fiscal year and $-0.87 EPS for the next fiscal year.

Cerecor Inc. (CERC) opened at 0.616 on Monday. The stock’s market capitalization is $8.67 million. Cerecor Inc. has a 1-year low of $0.34 and a 1-year high of $5.60. The company’s 50 day moving average is $0.71 and its 200-day moving average is $0.69.

In other news, Director Armistice Capital Master Fund acquired 72,672 shares of the company’s stock in a transaction that occurred on Friday, May 19th. The stock was purchased at an average price of $0.63 per share, with a total value of $45,783.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 10.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Cerecor Inc. (NASDAQ:CERC) Scheduled to Post Earnings on Monday” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/07/cerecor-inc-nasdaqcerc-scheduled-to-post-earnings-on-monday.html.

Cerecor Company Profile

Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.

Earnings History for Cerecor (NASDAQ:CERC)

Receive News & Stock Ratings for Cerecor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor Inc. and related stocks with our FREE daily email newsletter.